country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-152838

Copy Link Print Information

Gemlapodect

(Synonyms: RO554965)

Gemlapodect (RO554965) is an inhibitor of phosphodiesterase 10A (PDE10A). Gemlapodect can be used for researching schizophrenia.

For research use only. We do not sell to patients.

CAS No.: 1380329-87-2
Formula: C₂₂H₂₁N₇O₃
Molecular Weight:431.45

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (271 KB)

Gemlapodect Chemical Structure

CAS No.: 1380329-87-2

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vivo
- Clinical Trial
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Gemlapodect (RO554965) is an inhibitor of phosphodiesterase 10A (PDE10A). Gemlapodect can be used for researching schizophrenia^[1].

IC₅₀ & Target^[1]

PDE10A

All Phosphodiesterase (PDE) Isoforms :

In Vivo

Gemlapodect (5-15 mg; p.o.; once daily for 6 weeks) significantly improves the work and life social functions of Childhood-Onset Fluency Disorder (COFD) patients and shows biosafety^[2].
Gemlapodect (10 mg/kg; p.o.; single dose) shows nothing change in glucose tolerance of 9 weeks male SD rats^[2].
Gemlapodect (0.3 mg/kg; p.o.; once daily for 8 days) induces a slight glucose tolerance improvement, no changes in fasting blood glucose, and decreases of fasting insulin in 10 weeks male SD rats^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Adult male patients with COFD (18-50 years old)^[2].
Dosage:

5-15 mg.
Administration:

Oral gavage; once daily for 6 weeks.
Result:

Improved the Stuttering, work, social life, family life and home responsibilities of COFD patients and showed biosafety.

Animal Model:

9 weeks or 10 weeks male SD rats^[2].
Dosage:

0.3 mg/kg or 10 mg/kg.
Administration:

Oral gavage; once daily for 1 or 8 days.
Result:

Showed insignificantly change of glucose tolerance in healthy rats.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 1380329-87-2
Molecular Weight 431.45
Formula C₂₂H₂₁N₇O₃
SMILES

O=C(C1=C(C(N2CCOCC2)=O)C=NN1C)NC3=CC4=NC(C5=CC=CC=C5)=NN4C=C3
Synonyms

RO554965
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (271 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Zagorska A, et al. Phosphodiesterase 10 Inhibitors - Novel Perspectives for Psychiatric and Neurodegenerative Drug Discovery. Curr Med Chem. 2018;25(29):3455-3481. [Content Brief]

[2]. GARIBALDI, et al. METHODS FOR THE TREATMENT OF CHILDHOOD-ONSET FLUENCY DISORDER. World Intellectual Property Organization. WO2022162193

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote

Amount: USD 0.00

Biological Activity
- Description
- IC₅₀ & Target
- In Vivo
- Clinical Trial
Chemical Information
Purity & Documentation
References

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Gemlapodect

All Phosphodiesterase (PDE) Isoforms

Biological Activity

Chemical Information

Purity & Documentation

References

Calculators

Help & FAQs

Gemlapodect Related Classifications

HY-152838 Related Classifications